Trials / Completed
CompletedNCT00119665
Clinical Trial Assessing Toxicity and Efficacy of MF101 for Hot Flashes
A Phase II, Double-Blind, Placebo-Controlled, Randomized Clinical Trial Assessing Toxicity and Efficacy of MF101 for Hot Flashes and Menopausal Symptoms
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 180 (planned)
- Sponsor
- Bionovo · Industry
- Sex
- Female
- Age
- 40 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The researchers propose a Phase II randomized, double-blind, placebo-controlled trial of 180 healthy postmenopausal women experiencing at least 5 hot flashes per day or 35 hot flashes per week. Women will be randomized to one of three arms: 4.5 grams/day (dry weight of extract) of MF101, 9.0 grams/day (dry weight of extract) of MF101 or placebo for 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MF101 |
Timeline
- Start date
- 2006-02-01
- Completion
- 2007-02-01
- First posted
- 2005-07-14
- Last updated
- 2007-05-17
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00119665. Inclusion in this directory is not an endorsement.